KBC Group’s Sage Therapeutics SAGE Stock Holding History

KBC Group’s Portfolio SAGE Stock Details SAGE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-1,282	Closed	-$24K	–	1908
2024 Q1	$24K	Hold	1,282	–	–	﹤0.01%	1811
2023 Q4	$28K	Hold	1,282	–	–	﹤0.01%	1825
2023 Q3	$26K	Buy	+1,282	New	+$37K	﹤0.01%	1843

Other funds holding SAGE

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

KBC Group's SAGE Position: Q2 2024 in Review

KBC Group sold out of Sage Therapeutics (SAGE) in Q2 2024, closing a stake of 1,282 shares — an estimated $24K sold.

KBC Group first reported a position in SAGE in Q3 2023 and held it in 3 quarters. The position peaked at $28K in Q4 2023. 195 funds tracked by Wall St. Rank hold SAGE as of Q2 2024.

KBC Group reported no remaining Sage Therapeutics position as of Q2 2024 after selling out during the quarter.
KBC Group sold 1,282 Sage Therapeutics shares in Q2 2024, an estimated $24K.
KBC Group first reported a position in Sage Therapeutics in Q3 2023 and held it in 3 quarters.
KBC Group's Sage Therapeutics position peaked at $28K in Q4 2023.
195 funds tracked by Wall St. Rank held Sage Therapeutics as of Q2 2024.

Based on KBC Group's 13F filing for Q2 2024, filed 17 Jul 2024.